Update: 25.01.2021
Last week: 2 week 2022 (10.01.2022 - 16.01.2022)
Last full month: Dec 2021
| Time period | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | ||||||||
| WoW | 2 510 | 61.7% | 55.7% | 10.2 | 1 109 834 | 64.8% | 82.7% | 7.6 |
| MoM | 7 842 | -1.5% | 45.8% | -1.3 | 3 429 269 | -1.2% | 75.8% | -0.8 |
| YTD | 4 062 | 1.3% | 51.3% | -8 | 1 783 405 | 29.9% | 79.6% | -1.9 |
| MAT | 117 658 | -24.4% | 55.4% | -6.6 | 46 021 369 | -0.4% | 80.3% | -1 |
| CAPSICAM | ||||||||
| WoW | 23 200 | 28.8% | 3.6% | 0 | 9 523 703 | 28.5% | 4.0% | 0.1 |
| MoM | 106 383 | 11.1% | 4.0% | 0.5 | 43 240 220 | 11.8% | 4.3% | 0.6 |
| YTD | 41 213 | -3.9% | 3.6% | 0.2 | 16 935 193 | -6.9% | 3.9% | -0.1 |
| MAT | 1 063 429 | -19.5% | 3.2% | -0.2 | 437 701 743 | -7.7% | 3.5% | -0.2 |
| MILDRONATE | ||||||||
| WoW | 103 105 | 43.3% | 12.8% | 1.2 | 41 313 272 | 46.4% | 18.5% | 1.5 |
| MoM | 417 135 | -7.8% | 12.3% | -0.2 | 162 253 267 | -6.5% | 17.5% | 0.1 |
| YTD | 175 035 | 11.6% | 9.4% | 0.9 | 69 537 998 | 1.3% | 14.1% | 0.1 |
| MAT | 4 813 918 | 11.3% | 9.3% | 1.4 | 1 934 444 580 | 15.2% | 14.1% | 2.2 |
| SULFARGIN | ||||||||
| WoW | 3 382 | 47.9% | 1.0% | 0.2 | 1 656 636 | 45.1% | 1.4% | 0.3 |
| MoM | 17 478 | 36.4% | 1.2% | 0.3 | 8 443 597 | 31.0% | 1.7% | 0.4 |
| YTD | 5 669 | -3.7% | 0.9% | 0 | 2 798 478 | 2.4% | 1.3% | 0.2 |
| MAT | 163 933 | -21.8% | 0.8% | -0.1 | 79 825 913 | -9.0% | 1.2% | -0.1 |
| VIPROSAL | ||||||||
| WoW | 27 268 | 19.4% | 4.2% | -0.3 | 10 743 509 | 19.3% | 4.5% | -0.2 |
| MoM | 137 425 | -3.2% | 5.2% | 0 | 54 451 164 | -0.3% | 5.5% | 0.2 |
| YTD | 50 100 | 27.4% | 4.4% | 1.2 | 19 746 585 | 28.7% | 4.6% | 1.2 |
| MAT | 1 254 294 | -11.6% | 3.7% | 0.1 | 475 675 663 | -2.5% | 3.8% | 0 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 2 510 | 61.7% | 55.7% | 10.2 | 1 109 834 | 64.8% | 82.7% | 7.6 |
| CAPSICAM | 23 200 | 28.8% | 3.6% | 0 | 9 523 703 | 28.5% | 4.0% | 0.1 |
| MILDRONATE | 103 105 | 43.3% | 12.8% | 1.2 | 41 313 272 | 46.4% | 18.5% | 1.5 |
| SULFARGIN | 3 382 | 47.9% | 1.0% | 0.2 | 1 656 636 | 45.1% | 1.4% | 0.3 |
| VIPROSAL | 27 268 | 19.4% | 4.2% | -0.3 | 10 743 509 | 19.3% | 4.5% | -0.2 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 7 842 | -1.5% | 45.8% | -1.3 | 3 429 269 | -1.2% | 75.8% | -0.8 |
| CAPSICAM | 106 383 | 11.1% | 4.0% | 0.5 | 43 240 220 | 11.8% | 4.3% | 0.6 |
| MILDRONATE | 417 135 | -7.8% | 12.3% | -0.2 | 162 253 267 | -6.5% | 17.5% | 0.1 |
| SULFARGIN | 17 478 | 36.4% | 1.2% | 0.3 | 8 443 597 | 31.0% | 1.7% | 0.4 |
| VIPROSAL | 137 425 | -3.2% | 5.2% | 0 | 54 451 164 | -0.3% | 5.5% | 0.2 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 4 062 | 1.3% | 51.3% | -8 | 1 783 405 | 29.9% | 79.6% | -1.9 |
| CAPSICAM | 41 213 | -3.9% | 3.6% | 0.2 | 16 935 193 | -6.9% | 3.9% | -0.1 |
| MILDRONATE | 175 035 | 11.6% | 9.4% | 0.9 | 69 537 998 | 1.3% | 14.1% | 0.1 |
| SULFARGIN | 5 669 | -3.7% | 0.9% | 0 | 2 798 478 | 2.4% | 1.3% | 0.2 |
| VIPROSAL | 50 100 | 27.4% | 4.4% | 1.2 | 19 746 585 | 28.7% | 4.6% | 1.2 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 117 658 | -24.4% | 55.4% | -6.6 | 46 021 369 | -0.4% | 80.3% | -1 |
| CAPSICAM | 1 063 429 | -19.5% | 3.2% | -0.2 | 437 701 743 | -7.7% | 3.5% | -0.2 |
| MILDRONATE | 4 813 918 | 11.3% | 9.3% | 1.4 | 1 934 444 580 | 15.2% | 14.1% | 2.2 |
| SULFARGIN | 163 933 | -21.8% | 0.8% | -0.1 | 79 825 913 | -9.0% | 1.2% | -0.1 |
| VIPROSAL | 1 254 294 | -11.6% | 3.7% | 0.1 | 475 675 663 | -2.5% | 3.8% | 0 |
## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"Abbreviations
WoW - Week Over Week Change = Sales of the last week / Sales of the previous week - 1
MoM - Month Over Month Change = Sales of the last full month / Sales of the previous full month - 1
YTD - Year to Date - a period of time beginning the first day of the current calendar year up to the current date
MAT - Moving Annual Total - a period, being any 12 month period ending on the last week
MS - Market Share
Data Sources:
DSM: Sales
Palomars: TRPs
MI: Fact Digital Costs
MI Estimated Costs: TV costs